Stockreport
Cellectis Announces Two Oral Presentations and One Poster Presentation at the 2017 ASH Annual Meeting
Last cellectis sa ads earnings: 11/13 04:30 pm
Check Earnings Report
US:NASDAQ Investor Relations: cellectis.com/en/investors
PDF
NEW YORK--(BUSINESS WIRE)-- Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced today that abstracts regarding the Company's allogeneic, off-the-shelf, CAR T product candidates have been accepted for presentation at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition. The meeting will be held from December 9 to 12, 2017 in Atlanta, GA. Oral presentations: UCARTCS1 product candidate targeting Multiple Myeloma 502. Universal SLAMF7-Specific CAR T-Cells As Treatment for Multiple Myeloma Abstract: https://ash.confex.com/ash/2017/webprogram/Paper106073.htmlSession Name: 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Nov
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | CLLS | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
CLLS alerts
CLLS alerts
from News Quantified
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CLLS alerts
High impacting Cellectis SA ADS news events
Weekly update
A roundup of the hottest topics
CLLS
NEWS
NEWS
- Cellectis SA (NASDAQ: CLLS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating.[MarketBeat]
- Cellectis: Monthly Information on Share Capital and Company Voting Rights[Business Wire]
- Cellectis SA (NASDAQ: CLLS) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating.[MarketBeat]
- Cellectis SA (NASDAQ: CLLS) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $19.00 price target on the stock.[MarketBeat]
- Cellectis SA (NASDAQ: CLLS) is now covered by analysts at Goldman Sachs Group Inc. They set a "neutral" rating on the stock.[MarketBeat]
- More
CLLS
SEC Filings
SEC Filings
- 12/10/18 - Form 6-K
- 11/13/18 - Form 6-K
- 11/13/18 - Form 6-K
- CLLS's page on the SEC website
- More